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Background. Laparoscopic liver resection (LLR) has emerged as an alternative procedure to open liver resection in selected
patients. The purpose of this study was to describe our initial experience of 100 patients undergoing LLR. Methods. We analysed
a prospectively maintained hepatobiliary database of 100 patients who underwent LLR between August 2007 and August 2012.
Clinicopathological data were reviewed to evaluate surgical outcomes following LLR. Results. The median age was 64 and median
BMI 27. Patients had a liver resection for either malignant lesions (n = 74) or benign lesions (n = 26). Commonly performed
procedures were segmentectomy/metastectomy (n = 55), left lateral sectionectomy (LLS) (n = 26), or major hepatectomy (n = 19).
Complete LLR was performed in 84 patients, 9 were converted to open and 7 hand-assisted. The most common indications were
CRLM (n = 62), followed by hepatic adenoma (n = 9) or hepatocellular carcinoma (n = 7). The median operating time was 240
minutes and median blood loss was 250mL. Major postoperative complications occurred in 9 patients. The median length of stay
(LOS) was 5 days. One patient died within 30 days of liver resection. Conclusions. LLR is a safe and oncologically feasible procedure
with comparable short-term perioperative outcomes to the open approach. However, further studies are necessary to determine
long-term oncological outcomes.
1. Introduction
Since the initial report in 1992 by Gagner et al. laparoscopic
liver resection (LLR) has evolved for treating benign and
malignant tumours of the liver in selected patients [1–5].
As the technical innovations in the field of laparoscopic
surgery continue to evolvemore andmoreminimally invasive
liver surgery is being carried out in specialised centres [4–
15]. A review by Nguyen et al. in 2009 reported outcomes
following LLR of 2804 patients citing reduced intraoperative
blood loss reduced postoperative morbidity and mortality,
and shorter in-patient hospital stay [3], albeit with slightly
longer operating times [2]. Similar results have been reported
by other centres [9–14]. In general the benefits of LLR
are less surgical trauma associated with less postoperative
pain, reduced analgesic requirements, and an early return to
normal daily activities [13–18]. However, such findings have
never been proved by a randomised controlled trial, and start-
ing one now would be difficult as LLR has already become
an established procedure inmost specialist laparoscopic HPB
units [13–18].
LLR for benign lesions gained acceptance relatively early
on [1–5]; however, enthusiasm for laparoscopic resection
of malignant lesions developed rather slowly [1–3, 5, 7–13],
the major obstacles being oncologic inadequacy [10, 11] and
concerns over seeding of tumour cells at the time of surgery
and perhaps an increased risk of tumour recurrence [10–
13]. Moreover, in its infancy LLR carried with it concerns
regarding an increased risk of intraoperative bleeding and
air embolism [10]. However, recent advances in the surgical
techniques and development of more laparoscopic devices
have largely overcome these problems to a certain extent
[15–21]. Nevertheless, its long-term oncological outcome
and added benefit of improving quality of life are still yet
to be proven [10–14]. Perhaps for most enthusiasts in the
field minor LLRs have obvious advantages although major
hepatectomy is still very controversial.
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The aim of this study was to evaluate the clinical and
oncological outcomes of our first 100 LLRs performed in a
supraregional HPB and liver transplant unit in North East
England.
2. Methods
We analysed a prospectively maintained HPB database for
patients undergoing LLR between August 2007 and August
2012. The primary outcome measure was short-term surgical
outcome. The secondary end points were midterm overall
and disease-free survival. Three surgeons (D. M. Manas, J.
J. French, and S. A. White) have performed LLR in our
unit since 2007 and make up 10–15% of all liver resections.
Before surgery, each patient was individually evaluated in
our weekly multidisciplinary team (MDT) meeting with
surgeons, pathologists, oncologists, gastroenterologists, and
radiologists. All patients had an abdominal CT scan and liver-
specific double-contrast magnetic resonance imaging (MRI).
Patients with good performance status, resectable liver
disease, absence of extrahepatic disease, and sufficient func-
tional parenchymawere considered suitable for LLR. Patients
with tumours within 1 cm of the portal vein bifurcation, the
inferior vena cava, or hepatic vein confluence and tumours
involving the common hepatic duct were found unsuitable
for LLR.Moreover, large tumours (>10 cm) and the need for a
portal lymphadenectomy were also considered to be contra-
indications for a LLR in our early series.
Patient demographics, indications, type of liver resection,
intraoperative blood loss, duration of surgery (time from start
of skin incision to the end of wound closure), conversion
to open or hand-assisted, length of intensive care unit
(ICU) stay, postoperative length of stay (LOS), postoperative
complications, and mortality (within 30 days from surgery)
were evaluated. The histological reports were all reviewed to
assess resection margin status.
The extent of hepatic resection was recorded according
to the Brisbane 2000 terminology of liver anatomy and
resections [9]. Operative results and postoperative variables
were analysed for minor resections and major hepatectomies
(e.g., removal of three or more segments, right hepatectomy,
or left hepatectomy) where appropriate [3]. Postoperative
complications were classified as per the Dindo et al. [16]
classification. Margin status was defined as 𝑅
0
when micro-
scopically negative for tumour or 𝑅
1
for microscopically
positive for tumour existing within 1mm of the margin.
3. Surgical Technique
3.1. Patient Positioning. For resections of the left lateral seg-
ment and tumours in the anterior segments, for example, IVb,
V, and VI, we preferred a supine position with split legs with
the surgeon standing between the legs and assistants on either
side. Five ports (ENDO PATH Xcel, Ethicon Endo-Surgery,
LLC, USA) including three 12mm ports are positioned, one
supraumbilical port, two in the right and left midclavicular
line, and two 5mm ports in the right and left anterior axillary
line as described previously [17], but there has been a decrease
in the number of ports with more experience.
3.2. Pringle’s Manoeuvre. We always perform a staging lapa-
roscopy to rule out extrahepatic disease at the time of the LLR.
As part of the protocol a laparoscopic ultrasound (7.5MHz,
Aloka Co. Ltd., Tokyo, Japan) is performed to define the
vascular anatomy and to confirm the location of metastases.
Although various techniques for retracting the liver have
been used in our series, the authors prefer to divide the
falciform ligament and then place an Endoloop (Autosuture,
TycoHealthcare Ltd.) around the free edge of the ligamentum
teres. This can be retracted superiorly by bringing the suture
through the anterior abdominal wall using an Endo Close
(Autosuture, Tyco Healthcare UK Ltd.) device. The suture is
then held in a haemostat thus holding the ligament against
the anterior abdominal wall or laterally. The gall bladder can
also be used for retraction but some patientsmay have already
had this removed.
Once the liver has been retracted and the hepato-
duodenal ligament has been lifted a tape can then be placed,
acting as a tourniquet around the hepatoduodenal ligament
using a “Gold finger” (Gold finger, blunt dissector, Ethicon
Endo surgery, Johnson & Johnson, USA) as previously
described [17]. A nylon tape is passed through the snare in
the tip of the Gold finger (Ethicon Endo-Surgery, Johnson
& Johnson, USA). The Gold finger can be safely introduced
through a 10mm working port in the right upper quadrant
due to its blunt and atraumatic tip. The Gold finger is then
advanced around the porta hepatis until the tip of the nylon
tape can be visualised on the left side of the hepatoduodenal
ligament. The tape is then grasped through the port placed
in the left upper quadrant in the midclavicular line. The
two ends are positioned through the port onto the anterior
abdominal wall and placed through a “snugger” using tubing
(Suction tubing 10 cm, 7mm, Pennine Healthcare Ltd., UK).
The port is removed and then replaced with the tape lying
adjacent on the outside of the port. With increasing experi-
ence this step has sometimes not been required at all.
3.3. Hilar Dissection and Parenchymal Transection. All major
structures at the hilum are divided extrahepatically except
the hepatic bile duct which is divided within the liver
parenchyma using a suitable stapling device. Vascular staplers
with roticulators are used to manage major pedicles and
vessels. For right hepatectomy the right hepatic artery (RHA)
and the right portal vein (RPV) are approached either
anteriorly or laterally, usually posterior to the bile duct using
locking Weck Clips. The Glissonian approach as described
by Launois and Jamieson [21] was never used. Parenchymal
transection was performed using either a combination of the
cavitational ultrasonic aspirator (CUSA) or bipolar sealing
device Tissue Link, theHarmonic Scalpel ultrasonic activated
shears (Harmonic ACE) or Ligasure device. Tissue sealants
such as Tisseel or Evicel were applied to the cut surface of
the liver to further control bleeding from the parenchymal
transection margin. The specimen is retrieved in an Endo-
2 catch bag through a Pfannenstiel incision in most cases or
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Table 1: Patients characteristics and surgical outcome.
Variable Frequency
Age (median in years, range) 64 (22–84)
Sex (female :male) 52 : 48
BMI (median) 27 (16–40)
ASA grade (median) 2
Laparoscopic 84
HALR 7
Converted 9
through the previous midline incision if the indication was
colorectal liver metastases (CRLM).
3.4. Followup. After initial followup between 4 to 6 weeks,
all patients were regularly reviewed thereafter at 3, 6, 12, 18,
and 24 months and yearly thereafter for the first 5 years
for patients with malignant tumours. Patients with benign
liver tumours were followed appropriately depending on
their underlying pathological condition. Survival status was
determined by review of the patients’ medical records and
defined as the time interval from the date of initial operation
to the date of last clinical encounter or date of death if known.
3.5. Statistical Analysis. All results are expressed as median
and ranges. The Mann-Whitney 𝑈 test was applied to com-
pare nonparametric data and the chi-squared test or Fisher’s
exact test were applied for analysis of categorical variables.
Overall and disease-free survival was analysed by the Kaplan-
Meier method and their significance was assessed using the
log-rank test. The level of statistical significance was set at
𝑃 < 0.05.
4. Results
74 patients had LLR for malignant disease, whereas 26
patients had resections for benign disease. There were 52
female and 48 male patients. The median age of all patients
was 64 years (range 23–84 years) and median BMI was 27
(range 16–40) (Table 1).
Indications for surgery in the malignancy group were
CRLM (𝑛 = 62), hepatocellular carcinoma (HCC 𝑛 = 7),
intrahepatic cholangiocarcinoma (𝑛 = 3), lymphoma (𝑛 =
1), and metastases from breast cancer (𝑛 = 1). Among
the benign conditions the most common indications were
adenoma (𝑛 = 9), biliary/liver cyst (𝑛 = 6), haemangioma
(𝑛 = 5) (4 of these patients had a primary colorectal
tumour and were suspected CRLM; however, histology of
the resected liver revealed haemangioma, whereas one other
patient had underlying ovarian primary tumour and was
found to have indeterminate liver lesion, liver resection
revealing a haemangioma), focal nodular hyperplasia (FNH
𝑛 = 4), and angiomyolipoma (𝑛 = 2) (Table 2). The patient
with lymphoma had a previous primary colorectal tumour
that was thought to be a solitary secondary metastasis.
Table 2: Histological results in LLR 𝑛 = 100.
Malignant tumour 𝑛 = 74
Colorectal liver metastases 62
Hepatocellular carcinoma 7
Cholangiocarcinoma 3
Metastases from breast cancer 1
Lymphoma 1
Benign tumour 𝑛 = 26
Adenoma 9
Biliary/liver cyst 6
Haemangioma 5
Focal nodular hyperplasia (FNH) 4
Angiomyolipoma 2
Table 3: Type of liver resection.
Types of liver resection 𝑛 = 100
Anatomical liver resection (major) 19
Right hemihepatectomy 7
Left hemihepatectomy 6
Extended L hemihepatectomy 2
Trisegmentectomy 4
Nonanatomical liver resection 55
Left lateral sectionectomy (LLS) 26
Table 4: Location of tumours.
Segmental position of liver tumour Frequency (𝑛 = 81)
II 3
LLS (II, III) 16
III 7
IV, IVB 8
IV, V 6
V 9
V, VI 7
VI 8
VI, VII 12
VII 3
VIII 2
Major hepatectomy (𝑛 = 19).
Major hepatectomies were performed in 19 patients (19%)
and included 7 right hemihepatectomies, 6 left hemihepatec-
tomies, 2 extended left hemihepatectomies, and 4 trisegmen-
tectomies. Out of the 19 major hepatectomies, five patients
were converted to an open procedure and two patients had
hand-assisted liver resection (HALR) (Tables 5 and 7). In our
series complete laparoscopic liver resection was performed in
84 patients (84/100), 9 were converted to an open procedure
(Tables 3, 5, and 7) and 7 patients had a hand-assisted surgical
resection (HALR) (Tables 1 and 7). For the hand-assisted
technique a minilaparotomy in the right upper quadrant
or insertion of a handport was used for completion of the
parenchymal transection (Table 4).
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Table 5: Reasons for conversion to an open procedure.
Reason Frequency (𝑛 = 9)
Tumour in close proximity to large vessel
and concern over margin status 4
Difficult/prolonged hilar dissection 2
Unable to locate the tumour 1
Large bulky tumour/bleeding 2
Table 6: Perioperative outcome following LLR.
Variable Frequency
Size of tumour (mm) 35 (2–80)
Operation time (min) 240 (45–540)
Blood loss (mLs) 250 (30–1200)
Hospital stay (days) 5 (1–22)
Morbidity rate (%) 9 (9)
30-day mortality rate 1 (1%)
Median values.
Table 7: Major hepatectomy.
Variable Major hepatectomy(𝑛 = 19)
Operation time (mins) 302 (252-353)
Blood loss (mls) 481 (282–689)
Hospital stay (days) 8 (3–23)
Open conversion 5
HALR 2
Median (range values).
The median overall operative time was 240 minutes
(range 45–540 minutes), with a median blood loss of 250mL
(range 30–1200mL). The median length of stay was 5 days
(range 1–23 days) with a median of 1 day in either the
ITU or HDU (1–8 days) (Table 6). A blood transfusion was
required in only 11 patients. The median postoperative opiate
requirement was 40 mg (range 30–100mg). Moreover, in
patients undergoing a major hepatectomy, the median oper-
ating time was 302 minutes (252–540), the median blood loss
was 481mLs (range 282–689), and median length of stay was
8 days (range 3–23 days) (Table 7). For patients undergoing
LLS the median operative time was 195 minutes (range 45–
285 minutes), median blood loss was 175mLs (range 100–
450mL), median duration of analgesia requirement was 34
hours (range 8–62 hours), and median duration of hospital
stay was 3 days (range 1–14 days) (Table 6).
Significant postoperative complications (Clavien-Dindo
III/IV) occurred in 9 cases (9%) (Table 8). A bile leak
requiring conservative management or stent placement was
themost common complication (𝑛 = 3). A laparoscopic wash
out was needed in 2 patients, one for an intra-abdominal
haematoma and a second for an infected fluid collection,
whilst another patient having a right-sided subphrenic fluid
collection underwent an insertion of percutaneous radio-
logical drainage. Two patients developed chest infections
Table 8: Postoperative complications.
Complications Frequency Management
Bile leak 3
Conservative management
(𝑛 = 2)
Biliary stent placement (𝑛 = 1)
Intra-abdominal
collection/hematoma 3
2-laparoscopic washout (𝑛 = 2)
Percutaneous radiological
drainage
Small bowel
obstruction 1
Required laparotomy, small
bowel resection at day 27
Chest infections 2 Treated with antibiotic (𝑛 = 2)One required ITU admission
postoperatively requiring intravenous antibiotics, oxygen
therapy, and chest physiotherapy; however, one of them
deteriorated further and was shifted to the high dependency
unit. One patient was readmitted 4 weeks after liver resection
with signs and symptoms of small bowel obstruction, a
CT scan confirmed findings of small bowel obstruction
and thickening around a previous anastomosis. However, at
laparotomy recurrence of the primary tumour was found at
the previous anastomosis not detectable on previous imaging;
the tumour was resected completely (Table 8). In-patient
mortality was 1%. This patient developed a large pulmonary
embolism and died two days after the surgery.Thepatient was
on prophylactic Tinzaparin while on the ward.
In a carefully selected subset of patients undergoing
LLR for malignancy, complete surgical resection (𝑅
0
) was
achieved in 89% (𝑛 = 62, 𝑅
1
resection = 7) CRLM patients
and 72% (𝑛 = 7, 𝑅
1
resection = 2) for patients with HCC.
The median follow-up period was 14 months for CRLM
(0.2–50 months) and HCC (11–40 months), respectively. The
median recurrence-free survival was 18 months (range 8–28
months) in CRLM and 32 months (range 8–51 months) in
HCC patients. Overall 3-year survival for CRLMpatients was
78% with a median survival of 47 months (38–56 months)
(Figure 1). A total of 10 patients died in the follow-up period,
8 due to progression of underlying disease. One patient died
due to a cardiovascular event (3 years after liver resection)
and one patient developed sepsis from a pneumonia and died
from multiorgan failure 4 months after the liver resection.
5. Discussion
LLR has been established as a favourable alternative to an
open procedure to treat both benign and malignant diseases
of the liver [1–6] and hepatobiliary surgeons around theworld
are increasingly performing LLR with greater confidence [7–
13]. However, concerns still remain regarding parenchymal
transection methods, controlling bleeding, bile leaks, and
incomplete resection [3, 14–18]. This study suggests that LLR
is a feasible and safe procedure in selected patients. Patient
selection for LLR is still an issue and careful consideration
must be given to the indications for LLR, particularly the
position of the tumour, whether it is multifocal, and whether
the patient can withstand a prolonged pneumoperitoneum.
In our department each individual patient was discussed in
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Figure 1: Overall survival for CRLM after LLR.
a multidisciplinary team meeting (MDT) comprising hepat-
obiliary surgeons, a radiologist, a pathologist, and gas-
troenterologists; the decision regarding LLR was mutually
agreed. Generally patients with a large tumour (>10 cm) and
those involving major vasculature, for example, inferior vena
cava, or with invasion of other adjacent organs were found
unsuitable for LLR but not exclusively.
LLS and wedge resections were the most frequently
performed procedures. The Louisville Statement, 2008, has
recommended LLS as a standard technique for resection
of left-sided liver tumours [4] but in our experience we
would advise not taking on these types of resections early
on when tumours are close to the MHV/LHV confluence. In
our series the majority of patients had either nonanatomical
resections of segments (II, III, IVb, V, and VI) or LLS. Major
hepatectomies were performed in 19 cases (19%). Major hep-
atectomy (right or left hepatectomy or trisegmentectomy) is
a much more complex and technically demanding procedure
[17, 18] and can be associated with increased intraoperative
bleeding resulting in reduced exposure of the transection
plane and potentially the tumour margins [17–20]. Abu Hilal
et al. in their study of 133 patients undergoing LLR for
liver malignancies presented data of 42 major hepatectomies
[8]. Their results revealed major hepatectomies resulting in
increased blood loss, increased operating time, and increased
conversion rate [8]. Our results are similar to their findings.
However, wemaintained a low threshold for conversion to an
open procedure if the tumour size was large and difficult to
manipulate and mobilize or hemostasis was a major concern;
sometimes these issues were overcome by using a hand-
assisted procedure.
Our results have shown that the overall median operating
timewas 240minutes (range 45–540min) which is consistent
with most previous reports [8–21]. Some individual reports
comparing LLR to an open approach have reported shorter
operating times for open hepatic resection [21]. However, a
recent systematic review has found no significant difference
between laparoscopic and open liver resection with regards
to operating time [15]. Indeed with regards to LLS this is now
quicker than an open approach in our centre.
One added benefit of LLR is less intraoperative blood
loss and reduced blood transfusion requirements [2–10].
Our results revealed median intraoperative blood loss of
250mL (range 30–1200mL), similar to others [6, 12, 13, 20–
28]. In our experience only 11 patients required a blood
transfusionwhich is also similar to others [20–28].Webelieve
laparoscopic surgery provides better visualization of deep
vascular structures with more precise and accurate surgery
for tumours located in the left lateral and anterior segments.
We used a combination of various devices for parenchymal
transection to avoid excessive bleeding. These included a
Cavitron ultrasonic surgical aspirator (CUSA), Ligasure and
the Tissue link together facilitating excellent haemostasis and
clear anatomy.
LLR causes less tissue trauma consequently reducing
postoperative morbidity [3–9]. In our series only 9 patients
developed clinically significant complications. Our results
corroborate those of previous studies [7–11]. Another advan-
tage of LLR is minimal scarring and potentially fewer
adhesions thereby increasing the feasibility of a repeat liver
resection [11]. Recent reports suggest no significant survival
difference between primary and repeat liver resection [13–17].
Proponents of laparoscopic surgery claim shorter in-
hospital stays for patients undergoing LLR [11–19]. Our
results revealed an in-patient stay of 5 days (range 1–23 days).
These results support the findings of previous reports in
the literature [3–9]. Using our learning curve and enhanced
recovery techniques LLS patients can be discharged home the
next day or in most cases on the 2nd or 3rd postoperative
day. Shorter hospital stay helps reduce cost for organisa-
tions during difficult economic circumstances [12]. However,
overall cost effectiveness of the procedure is also dependent
on theatre time and the cost of instruments, which critics
believe is much higher in laparoscopic surgery [20]. Recent
reports in the literature suggest equivalent cost for open and
LLR [9, 13]. In addition, introduction of enhanced recovery
programmes in hepatobiliary surgery may further increase
the cost-effectiveness of LLR. However, only future studies
looking specifically at economic evaluation of laparoscopic
and open liver resection during the era of enhanced recovery
programmes would be able to answer these questions.
Oncologic adequacy of LLR has frequently been reported
in the literature [5–9, 13–17] and there is a trend amongstmost
hepatobiliary surgeons that LLR is a safe and an oncologically
feasible procedure in carefully selected patients [3–14]. Our
results have shown that of 74 patients undergoing LLR for
malignant lesions complete surgical resection was achieved
in 89% of patients with CRLM and 72% in patients with
HCC. These results coincide well with previous reports [19–
27]. Without any treatment the median survival of patients
with CRLM is 6 to 9 months [26] but now long-term survival
after liver resection has been reported to be up to 60% in
some studies [2, 3, 7, 13–25]. Our results revealed a median
disease-free survival of 18 months (range 8–28 months) in
those with CRLM and 32 months (range 8–51 months) in
those with HCC although numbers are far too small in
the latter case to make any useful conclusion. Moreover,
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overall 3-year survival following laparoscopic liver resection
for CRLM was 78%. Abu Hilal et al. in their study of 133
patients undergoing LLR for various hepatic malignancies
reported a 78% overall 2-year survival and 64% disease-free
survival for CRLM patients [8]. They have also reported a
77% overall 2-year survival in HCC patients [6]. Our survival
data are comparable with various other series in the literature
demonstrating feasible medium term survival following liver
resection for malignant lesions [13–31].
Important limitations to our study are the relatively
small sample size, yet it is still one of the largest series
reported inEurope.Nonetheless, our results coincidewith the
majority of previously reported series [9–19]. Furthermore,
in the absence of a randomised controlled trial, case series
will continue to provide further evidence to our existing
knowledge regarding LLR. Major obstacles to conducting a
RCT would be patient selection and randomising to an “open
resection” as LLR has already become the gold standard in
some specialist centres.
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